M. Gillison

发表

NRG-HN002: A Randomized Phase II Trial for Patients With p16-Positive, Non-Smoking-Associated, Locoregionally Advanced Oropharyngeal Cancer

Christopher U. Jones, C. Chung, J. Waldron, 2019, International Journal of Radiation Oncology*Biology*Physics.

Human papillomavirus and survival of patients with oropharyngeal cancer.

K. Ang, R. Weber, C. Chung, 2010, The New England journal of medicine.

Genome-wide analysis of HPV integration in human cancers reveals recurrent, focal genomic instability

T. Ried, H. Padilla‐Nash, T. Teknos, 2014, Genome research.

Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.

A. Cmelak, W. Westra, Sigui Li, 2008, Journal of the National Cancer Institute.

NCCN Guidelines ® Insights Head and Neck Cancers , Version 2 . 2017 Featured Updates to the NCCN Guidelines

Bharat B. Mittal, Jill Gilbert, Loren K. Mell, 2017 .

Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications

Christine H Chung, C. Chung, M. Gillison, 2009, Clinical Cancer Research.

Head and Neck Cancers, Version 1.2015.

J. Shah, R. Weber, A. Jimeno, 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522.

Sue S Yom, Wade L Thorstad, Adam S Garden, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gender Differences in Sexual Biomarkers and Behaviors Associated With Human Papillomavirus-16, −18, and −33 Seroprevalence

A. Alberg, A. Kreimer, M. Gillison, 2004, Sexually transmitted diseases.

Title : Associations between oral HPV 16 infection and cytopathology : evaluation of an oropharyngeal “ Pap-test equivalent ” in high-risk populations

D. Clark, M. Gillison, C. Fakhry, 2011 .

Associations between Oral HPV16 Infection and Cytopathology: Evaluation of an Oropharyngeal “Pap-Test Equivalent” in High-Risk Populations

D. Clark, M. Gillison, C. Fakhry, 2011, Cancer Prevention Research.

Head and neck cancers.

J. Shah, R. Weber, G. Sanguineti, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Head and Neck Squamous Cell Cancers in the Nonsmoker-Nondrinker

M. Gillison, G. D’Souza, 2005 .

Transcervical Ultrasonography Is Feasible to Visualize and Evaluate Base of Tongue Cancers

B. Messing, R. Blanco, G. Neuner, 2014, PloS one.

Human papillomavirus and prognosis of oropharyngeal squamous cell carcinoma: implications for clinical research in head and neck cancers.

M. Gillison, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus in head and neck squamous cell carcinoma: are some head and neck cancers a sexually transmitted disease?

W. Koch, K. Shah, M. Gillison, 1999, Current opinion in oncology.

Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Yoshimi Anzai, Thomas Galloway, Sue S Yom, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Christopher U. Jones, E. Sturgis, P. Harari, 2019, The Lancet.

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Susan M. Chang, A. M. López, R. Schilsky, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe.

D. Pardoll, T. Wu, S. Pai, 2003, Vaccine.

Head and Neck Cancers, Version 2.2014

Renato Martins, Bharat B. Mittal, Jill Gilbert, 2014 .

Reply to B. O'Sullivan et Al.

A. Garden, A. El‐Naggar, Q. Zhang, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of trastuzumab (T), paclitaxel (P) and cisplatin (C) in metastatic (M) or recurrent (R) head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status.

B. Murphy, M. Gillison, M. Kies, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus in HNSCC: recognition of a distinct disease type.

M. Gillison, Laura Vidal, 2008, Hematology/oncology clinics of North America.

Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.

G. Neuner, A. Blackford, M. Gillison, 2019, JAMA oncology.

Variations in HPV function are associated with survival in squamous cell carcinoma.

Jing Wang, Y. Xi, J. Califano, 2019, JCI insight.

Larynx preservation in head and neck cancers. A discussion of the National Comprehensive Cancer Network Practice Guidelines.

M. Gillison, A. Forastiere, 1999, Hematology/oncology clinics of North America.

Mucosal Melanoma of the Head and Neck Clinical Practice Guidelines in Oncology

K. Ang, J. Shah, R. Weber, 2012 .

Oropharyngeal carcinoma: A unique human papillomavirus-associated tumor of the head and neck

R. Jordan, M. Gillison, A. Zante, 2011 .

Long-term Persistence of Oral HPV Over 7 Years of Follow-up

M. Gillison, H. Strickler, C. Fakhry, 2020, JNCI cancer spectrum.

May 2 , 2019 Association of Oral Human Papillomavirus DNA Persistence With Cancer Progression After Primary Treatment for Oral Cavity and Oropharyngeal Squamous Cell Carcinoma

G. Neuner, A. Blackford, M. Gillison, 2019 .

Human Papillomavirus-16 Associated Adenocarcinoma NOS of Base of Tongue

B. Perez-Ordonez, J. Irish, E. Yu, 2013, Head and Neck Pathology.

Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)

Christopher U. Jones, P. Xia, C. Chung, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)

E. Mendez, C. Chung, R. Ferris, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies

V. Grégoire, J. Waldron, R. Ferris, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

In Regard to Bossi et al.

Christopher U. Jones, R. Weber, É. Vigneault, 2018, International journal of radiation oncology, biology, physics.

Sinonasal adenoid cystic carcinoma: Treatment outcomes and association with human papillomavirus

R. Carrau, A. Bhatt, Lai Wei, 2017, Head & neck.

E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group.

C. Chung, A. Cmelak, R. Ferris, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population.

A. Chaturvedi, H. Katki, M. Gillison, 2016, Oral oncology.

Oropharyngeal cancer survivorship in Denmark, 1977-2012.

M. Gillison, D. Eisele, C. Fakhry, 2015, Oral oncology.

Dose De-escalation in Human Papillomavirus-Associated Oropharyngeal Cancer: First Tracks on Powder.

S. Yom, M. Gillison, A. Trotti, 2015, International journal of radiation oncology, biology, physics.

Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.

J. Shah, R. Weber, A. Jimeno, 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

The Fanconi Anemia Pathway Limits Human Papillomavirus Replication

Elizabeth E. Hoskins, G. Nuovo, D. Witte, 2012, Journal of Virology.

Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin.

K. Shah, M. Ansari-Lari, W. Westra, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Head and neck surgical oncology in the time of a pandemic: Subsite‐specific triage guidelines during the COVID‐19 pandemic

M. Chambers, R. Weber, E. Sturgis, 2020, Head & neck.

ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).

C. Chung, A. Cmelak, R. Ferris, 2012 .

Case-control study of human papillomavirus and oropharyngeal cancer.

Carole Fakhry, Gypsyamber D'Souza, M. Pawlita, 2007, The New England journal of medicine.

Prevalence of cervical and oral human papillomavirus infections among US women.

E. Unger, M. Gillison, M. Steinau, 2014, The Journal of infectious diseases.

High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010.

B. Graubard, A. Chaturvedi, M. Gillison, 2014, The Journal of infectious diseases.

Automated high throughput DNA isolation for detection of human papillomavirus in oral rinse samples.

Xin He, M. Gillison, Tatevik R Broutian, 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Two-Week versus Six-Month Sampling Interval in a Short-Term Natural History Study of Oral HPV Infection in an HIV-Positive Cohort

E. Sugar, M. Gillison, C. Fakhry, 2010, PLoS ONE.

Oral Human Papillomavirus Infection Before and After Treatment for Human Papillomavirus 16–Positive and Human Papillomavirus 16–Negative Head and Neck Squamous Cell Carcinoma

W. Westra, W. Koch, Y. Agrawal, 2008, Clinical Cancer Research.

Analysis of the Effect of DNA Purification on Detection of Human Papillomavirus in Oral Rinse Samples by PCR

E. Sugar, M. Gillison, P. Gravitt, 2005, Journal of Clinical Microbiology.

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

D. Sidransky, M. Zahurak, W. Westra, 2000, Journal of the National Cancer Institute.

Prognostic impact of leukocyte counts before and during radiotherapy for oropharyngeal cancer

A. Garden, E. Sturgis, D. Rosenthal, 2017, Clinical and translational radiation oncology.

Human Papillomavirus (HPV) 16 E6 seropositivity is elevated in subjects with oral HPV16 infection.

Ross D. Cranston, J. Margolick, M. Pawlita, 2016, Cancer epidemiology.

HPV and prognosis for patients with oropharynx cancer.

M. Gillison, 2009, European journal of cancer.

Detection of Human Papillomavirus-16 in Fine-NeedleAspirates to DetermineTumor Origin in Patients withMetastatic Squamous Cell Carcinoma of the Head and Neck

M. Gillison, S. Begum, T. Nicol, 2007 .

Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma

M. Zahurak, W. Westra, M. Gillison, 2005, Clinical Cancer Research.

A new link between Fanconi anemia and human papillomavirus-associated malignancies.

D. Lowy, M. Gillison, 2003, Journal of the National Cancer Institute.

Real-Time Quantitative PCR Demonstrates Low Prevalence of Human Papillomavirus Type 16 in Premalignant and Malignant Lesions of the Oral Cavity 1

J. Califano, D. Sidransky, W. Westra, 2002 .

Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity.

J. Califano, D. Sidransky, W. Westra, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma.

D. Sidransky, W. Westra, W. Koch, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).

C. Chung, R. Ferris, W. Westra, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus and rising oropharyngeal cancer incidence in the United States.

Esther Kim, Sean Altekruse, Philip S Rosenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Feasibility and acceptance of oral HPV detection in the dental office: results from the National Dental PBRN

E. Funkhouser, G. Gilbert, M. Gillison, 2019 .

Feasibility and acceptance of oral human papillomavirus detection in the dental office: Results from The National Dental Practice-Based Research Network.

E. Funkhouser, G. Gilbert, M. Gillison, 2019, Journal of the American Dental Association.

Effect of Prophylactic Human Papillomavirus (HPV) Vaccination on Oral HPV Infections Among Young Adults in the United States.

B. Graubard, A. Chaturvedi, M. Gillison, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence and risk factors for oral DNA tumor viruses in HIV‐infected youth

Jiahong Xu, E. Secord, M. Gillison, 2016, Journal of medical virology.

High Oral Human Papillomavirus Type 16 Load Predicts Long-term Persistence in Individuals With or at Risk for HIV Infection.

Ross D. Cranston, J. Margolick, R. Burk, 2015, The Journal of infectious diseases.

Tobacco use and oral HPV-16 infection.

M. Gillison, C. Fakhry, G. D’Souza, 2014, JAMA.

HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS : SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING , NOVEMBER

A. Giuliano, A. Chaturvedi, W. Westra, 2009 .

HEAD AND NECK SQUAMOUS CELL CANCER AND THE HUMAN PAPILLOMAVIRUS: SUMMARY OF A NATIONAL CANCER INSTITUTE STATE OF THE SCIENCE MEETING,

A. Giuliano, A. Chaturvedi, W. Westra, 2009 .

Analysis of the effect of p16 and tobacco pack-years (p-y) on overall (OS) and progression-free survival (PFS) for patients with oropharynx cancer (OPC) in Radiation Therapy Oncology Group (RTOG) protocol 9003.

K. Ang, M. Hammond, C. Chung, 2010 .

Evolution of the Oropharynx Cancer Epidemic in the United States: Moderation of Increasing Incidence in Younger Individuals and Shift in the Burden to Older Individuals.

P. Rosenberg, A. Chaturvedi, Z. Zumsteg, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC).

A. Garden, K. Ang, R. Weber, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship between Prevalent Oral and Cervical Human Papillomavirus Infections in Human Immunodeficiency Virus-Positive and -Negative Women

E. Sugar, M. Gillison, H. Minkoff, 2006, Journal of Clinical Microbiology.

Sex Differences in Risk Factors and Natural History of Oral Human Papillomavirus Infection.

E. Sugar, M. Gillison, W. Xiao, 2016, The Journal of infectious diseases.

Gender differences in risk factors and natural history of oral human papillomavirus ( HPV ) infection

E. Sugar, M. Gillison, W. Xiao, 2016 .

University of Dundee Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer

Gioia Di Credico, A. Olshan, R. Hayes, 2019 .

Comprehensive control of human papillomavirus infections and related diseases.

M. Poljak, D. Forman, J. Cuzick, 2013, Vaccine.

Six‐month natural history of oral versus cervical human papillomavirus infection

K. Anastos, J. Palefsky, E. Sugar, 2007, International journal of cancer.

Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129.

C. Chung, W. Westra, R. Jordan, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States.

A. Chaturvedi, W. Anderson, E. Engels, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Behavioral, Immunologic, and Virologic Correlates of Oral Human Papillomavirus Infection in HIV-Infected Youth

Jiahong Xu, E. Secord, M. Gillison, 2015, Sexually transmitted diseases.

Oral Human Papillomavirus (HPV) Infection among Unvaccinated High-Risk Young Adults

A. Griffioen, M. Gillison, W. Xiao, 2014, Cancers.

Infection with Human Papilloma Virus (HPV) and risk of subsites within the oral cancer.

S. Franceschi, P. Boffetta, S. Schwartz, 2021, Cancer epidemiology.

Oral sexual behaviors associated with prevalent oral human papillomavirus infection.

Y. Agrawal, M. Gillison, G. D’Souza, 2009, The Journal of infectious diseases.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

K. Harrington, M. Monga, E. Vokes, 2018, The oncologist.

Human papillomavirus–associated head and neck squamous cell carcinoma: mounting evidence for an etiologic role for human papillomavirus in a subset of head and neck cancers

K. Shah, M. Gillison, 2001, Current opinion in oncology.

Intratumoral heterogeneity and clonal evolution induced by HPV integration

K. Coombes, Sara Goodwin, F. Sedlazeck, 2022, bioRxiv.

Head and neck cancers.

J. Shah, R. Weber, G. Sanguineti, 2011, Journal of the National Comprehensive Cancer Network : JNCCN.

Nivolumab for Squamous-Cell Cancer of Head and Neck.

R. Ferris, M. Gillison, 2017, The New England journal of medicine.

Abstract CT099: Nivolumab (nivo) vs investigator's choice (IC) for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CheckMate-141

K. Harrington, M. Monga, E. Vokes, 2016 .

Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.

K. Harrington, M. Monga, E. Vokes, 2016 .

Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141

K. Harrington, E. Vokes, R. Ferris, 2022, The oncologist.

Organ Preservation in Head and Neck Cancer

M. Gillison, A. Forastiere, 2003 .

Comprehensive control of human papillomavirus infections and related diseases.

M. Poljak, D. Forman, J. Cuzick, 2013, Vaccine.

Head and Neck Cancer Risk Prediction Models for the US Population from the INHANCE Consortium.

H. Morgenstern, A. Olshan, D. Winn, 2019, American journal of epidemiology.

Long‐term survival of a patient with leptomeningeal involvement by nasopharyngeal carcinoma after treatment with high‐dose intravenous methotrexate

N. Aygun, W. Westra, M. Gillison, 2012, Head & neck.

Human retinoblastoma is not caused by known pRb‐inactivating human DNA tumor viruses

B. Gallie, Ning Chen, M. Gillison, 2007, International journal of cancer.

Intratumoral Heterogeneity and Clonal Evolution Induced by HPV Integration

K. Coombes, Sara Goodwin, F. Sedlazeck, 2022, bioRxiv.

Human papillomavirus and the landscape of secondary genetic alterations in oral cancers

Anne-Katrin Emde, K. Coombes, Heather Geiger, 2018, Genome research.

Diverse tumorigenic consequences of human papillomavirus integration in primary oropharyngeal cancers

Anne-Katrin Emde, K. Coombes, Heather Geiger, 2021, bioRxiv.

HPV positive neuroendocrine cervical cancer cells are dependent on Myc but not E6/E7 viral oncogenes

S. Agarwal, T. Ried, C. Albanese, 2017, Scientific Reports.

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651

R. Ferris, A. Argiris, R. Haddad, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.

J. Shah, G. Weinstein, R. Weber, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141)

R. Ferris, C. Yen, Jin-Hyoung Kang, 2020, Head & neck.

Pathology Characterization and Detection of Human Papillomavirus Type 16 in Rectal Squamous Cell Carcinomas.

A. Bellizzi, C. Lynch, E. Engels, 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Representative oral microbiome data for the US population: the National Health and Nutrition Examination Survey.

E. Vogtmann, X. Hua, Jianxin Shi, 2022, The Lancet. Microbe.

Herd Protection Against Oral HPV Infection-Reply.

B. Graubard, A. Chaturvedi, M. Gillison, 2020, JAMA.

Clonal cytogenetic abnormalities and BCL2 rearrangementin interdigitating dendritic cell sarcoma

M. Borowitz, K. Murphy, C. Griffin, 2006, Leukemia & lymphoma.

Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus.

K. Shah, E. S. Garrett, A. Alberg, 2004, The Journal of infectious diseases.

Risk Factors for Oral HPV Infection among a High Prevalence Population of HIV-Positive and At-Risk HIV-Negative Adults

Ross D. Cranston, J. Margolick, R. Burk, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma.

Carole Fakhry, A. Chaturvedi, W. Anderson, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

NCCN Guidelines ® Insights Head and Neck Cancers , Version 1 . 2018 Featured Updates to the NCCN Guidelines

R. Weber, A. Jimeno, M. Witek, 2018 .

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

K. Harrington, M. Monga, E. Vokes, 2016, The New England journal of medicine.

Elective versus Therapeutic Neck Dissection in Oral Cancer.

S. Yom, M. Gillison, C. Fakhry, 2015, The New England journal of medicine.

Comprehensive control of human papillomavirus infections and related diseases.

M. Plummer, M. Poljak, J. Ferlay, 2013, Vaccine.

Current topics in the epidemiology of oral cavity and oropharyngeal cancers

M. Gillison, Maura L. Gillison, Maura L. Gillison, 2007, Head & neck.

Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection

M. Gillison, 2009, Current opinion in oncology.

Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma.

T. Wu, M. Gillison, Kalpana M. Devaraj, 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

T .-C . Wu CARCINOMA DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL

T. Wu, M. Gillison, Kalpana M. Devaraj, 2003 .

Validation of Methods for Oropharyngeal Cancer HPV Status Determination in US Cooperative Group Trials

Xin He, B. Perez-Ordonez, R. Jordan, 2012, The American journal of surgical pathology.

An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth.

James J Foti, E. Jaffee, Kwok-Kin Wong, 2021, Cancer discovery.

EUROGIN 2011 roadmap on prevention and treatment of HPV‐related disease

Y. Qiao, L. Bruni, A. Giuliano, 2012, International journal of cancer.

Racial differences in the relationship between tobacco, alcohol, and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE Consortium

H. Morgenstern, A. Olshan, D. Winn, 2018, Cancer Causes & Control.

Proton Beam Therapy for Head and Neck Carcinoma of Unknown Primary: Toxicity and Quality of Life

A. Garden, E. Sturgis, D. Rosenthal, 2021, International journal of particle therapy.

Alterations in oral bacterial communities are associated with risk factors for oral and oropharyngeal cancer

Timothy L. Tickle, Erica M. Hartmann, Jennifer R. Rider, 2017, Scientific Reports.

DEK promotes HPV positive and negative head and neck cancer cell proliferation

Grace E. Hallenbeck, D. Witte, P. Lambert, 2014, Oncogene.

Burden of potentially human papillomavirus‐associated cancers of the oropharynx and oral cavity in the US, 1998–2003

S. Coughlin, M. Reichman, Xiaocheng Wu, 2008, Cancer.

Assessing the Burden of HPV-Associated Cancers in the United States HPV Prophylactic Vaccines and the Potential Prevention of Noncervical Cancers in Both Men and Women

D. Lowy, A. Chaturvedi, M. Gillison, 2008 .

Elevated incidence of lung cancer among HIV-infected individuals.

Richard D Moore, Jinbo Chen, M. Brock, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers.

W. Westra, E. Sugar, M. Gillison, 2008, Journal of the National Cancer Institute.

Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis.

L. Alemany, X. Castellsagué, P. Snijders, 2012, Vaccine.

Prevalence of oral HPV infection in the United States, 2009-2010.

B. Graubard, A. Chaturvedi, M. Gillison, 2012, JAMA.

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

K. Harrington, E. Vokes, R. Ferris, 2019, Cancer.

Human papillomavirus-related oropharyngeal cancer

L. Alemany, M. Gillison, R. Mesía, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

NHANES 2009-2012 Findings: Association of Sexual Behaviors with Higher Prevalence of Oral Oncogenic Human Papillomavirus Infections in U.S. Men.

B. Graubard, A. Chaturvedi, M. Gillison, 2015, Cancer research.

Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Quynh-Thu Le, Qian Wu, Mitchell Machtay, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

A. Garden, Q. Zhang, Q. Le, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

K. Harrington, N. Lee, R. Ferris, 2019, Journal of Immunotherapy for Cancer.

Immunotherapy of Head and Neck Cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 9-10, 2014, Bethesda, Maryland

B. Fox, D. Brizel, L. Butterfield, 2016 .

Defects in the Fanconi Anemia Pathway in Head and Neck Cancer Cells Stimulate Tumor Cell Invasion through DNA-PK and Rac1 Signaling

Elizabeth E. Hoskins, K. Komurov, S. Potter, 2015, Clinical Cancer Research.

TIGIT as a therapeutic target of HPV-positive head and neck squamous cell carcinomas

D. Bell, A. Reuben, X. Le, 2021, medRxiv.

Head and Neck Cancers, Version 2.2013

K. Ang, J. Shah, R. Weber, 2013 .

Head and Neck Cancers , Version 1 . 2015 Featured Updates to the NCCN Guidelines

J. Shah, R. Weber, D. Brizel, 2015 .

Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and survival in the United States.

P. Rosenberg, S. Altekruse, M. Goodman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651

R. Ferris, A. Argiris, U. Müller-Richter, 2021, Annals of Oncology.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

K. Harrington, E. Vokes, R. Ferris, 2018, Oral oncology.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

K. Harrington, E. Vokes, R. Ferris, 2019, Clinical Cancer Research.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

K. Harrington, M. Monga, E. Vokes, 2017, The Lancet. Oncology.

1043OTreatment beyond progression with nivolumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: A biomarker analysis and updated clinical outcomes

K. Harrington, M. Monga, E. Vokes, 2017 .

Abstract CT022: Evaluation of oral microbiome profiling as a response biomarker in squamous cell carcinoma of the head and neck: Analyses from CheckMate 141

K. Harrington, M. Monga, E. Vokes, 2017 .

Independent association of marijuana use and poor oral hygiene with HPV–negative but not HPV–positive head and neck squamous cell carcinomas

M. Gillison, J. Shewale, W. Xiao, 2021, Cancer.

Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.

Jacques Ferlay, Philip S Rosenberg, J. Ferlay, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alcohol drinking and head and neck cancer risk: the joint effect of intensity and duration

H. Morgenstern, A. Olshan, W. Ahrens, 2020, British Journal of Cancer.

Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.

M. Carrington, F. Bray, S. Chanock, 2020, Oral oncology.

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results

Jason M. Johnson, A. Garden, J. Lee, 2020, Clinical Cancer Research.

Risk factors for acquisition and clearance of oral human papillomavirus infection among HIV-infected and HIV-uninfected adults.

Ross D. Cranston, J. Margolick, R. Burk, 2015, American journal of epidemiology.

Safety of nivolumab added to chemoradiotherapy platforms for intermediate and high-risk local-regionally advanced head and neck squamous cell carcinoma: RTOG Foundation 3504.

W. Curran, R. Ferris, Q. Le, 2022, International journal of radiation oncology, biology, physics.

Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer.

T. Wise-Draper, M. Gillison, X. Le, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma

J. Hopkins, D. Hong, C. Pickering, 2023, JCO precision oncology.

A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.

M. Monga, R. Ferris, C. Yen, 2017, Oral oncology.

Chapter 9: Role of mucosal human papillomavirus in nongenital cancers.

K. Shah, M. Gillison, 2003, Journal of the National Cancer Institute. Monographs.

Delayed Diagnosis and Elevated Mortality in an Urban Population With HIV and Lung Cancer: Implications for Patient Care

Richard D Moore, J. Herman, S. Baylin, 2006, Journal of acquired immune deficiency syndromes.

Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.

A. Giuliano, A. Chaturvedi, W. Westra, 2009, Head & neck.

Chapter 16: HPV vaccines in immunocompromised women and men.

J. Palefsky, M. Gillison, H. Strickler, 2006, Vaccine.

Eurogin Roadmap: Comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix

S. Franceschi, M. Goodman, X. Castellsagué, 2014, International journal of cancer.

Recurrent or metastatic head and neck squamous cell carcinoma that is not responsive to platinum-based chemotherapy progresses very rapidly , and patients have a very poor prognosis , ”

K. Harrington, M. Monga, E. Vokes, 2016 .

Significant changes in sexual behavior after a diagnosis of human papillomavirus‐positive and human papillomavirus‐negative oral cancer

M. Katz, M. Gillison, C. Fakhry, 2017, Cancer.

Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas.

B. Perez-Ordonez, R. Jordan, M. Lingen, 2013, Oral oncology.

Assessment of Human Papillomavirus in Lung Tumor Tissue

S. Wacholder, A. Goldstein, P. Taylor, 2011, Journal of the National Cancer Institute.

Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity.

M. Gillison, Maura L Gillison, 2004, Seminars in oncology.

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods

C. Wheeler, M. Schiffman, W. Quint, 2015, BMC Infectious Diseases.

Development and Validation of Nomograms Predictive of Overall and Progression-Free Survival in Patients With Oropharyngeal Cancer.

Christopher U. Jones, R. Weber, Q. Zhang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity.

K. Ang, R. Weber, C. Chung, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma.

P. Harari, C. Chung, Q. Zhang, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer.

K. Ang, C. Chung, Q. Zhang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Prevalence and Incidence of Oral Human Papillomavirus Infection Among Young Men and Women, Aged 18–30 Years

Xin He, M. Gillison, Tatevik R Broutian, 2012, Sexually transmitted diseases.

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

K. Harrington, R. Ferris, P. Brossart, 2019, Oral oncology.

Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234.

K. Ang, P. Harari, Q. Zhang, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.

Gypsyamber D'Souza, K. Anderson, S. Pai, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical implications of human papillomavirus in head and neck cancers.

M. Gillison, C. Fakhry, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HPV vaccines in immunocompromised women and men

J. Palefsky, M. Gillison, H. Strickler, 2006 .

893P Clinico-genetic profiling of HRAS mutant head and neck squamous cell carcinoma (HNSCC)

D. Hong, M. Gillison, X. Le, 2021, Annals of Oncology.

Natural history of anal vs oral HPV infection in HIV-infected men and women.

E. Sugar, M. Gillison, G. D’Souza, 2013, The Journal of infectious diseases.

The association of medication use with clearance or persistence of oral HPV infection

Ross D. Cranston, J. Margolick, R. Burk, 2016, Cancer Causes & Control.

HPV integration hijacks and multimerizes a cellular enhancer to generate a viral-cellular super-enhancer that drives high viral oncogene expression

Mirit I Aladjem, Keiko Akagi, Haiqing Fu, 2018, PLoS genetics.

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.

C. Chung, H. Quon, A. Sikora, 2015, JAMA oncology.

Human papillomavirus-related diseases: oropharynx cancers and potential implications for adolescent HPV vaccination.

M. Gillison, 2008, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach.

H. Morgenstern, A. Olshan, W. Ahrens, 2019, Oral oncology.

Prevalence of Oral HPV Infection in Unvaccinated Men and Women in the United States, 2009-2016.

B. Graubard, A. Chaturvedi, M. Gillison, 2019, JAMA.

Human Papillomavirus and Oropharyngeal Cancer Stage.

M. Gillison, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Moderate predictive value of demographic and behavioral characteristics for a diagnosis of HPV16-positive and HPV16-negative head and neck cancer.

R. Meyer, W. D'Souza, H. Zhang, 2010, Oral oncology.

Detection of Human Papillomavirus-16 in Fine-Needle Aspirates to Determine Tumor Origin in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck

W. Westra, M. Gillison, S. Begum, 2007, Clinical Cancer Research.

Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma.

A. Hui, L. Dawson, J. Waldron, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of NRG oncology/RTOG‐0129 risk groups for HPV‐positive and HPV‐negative oropharyngeal squamous cell cancer: Implications for risk‐based therapeutic intensity trials

R. Weber, Q. Zhang, S. Yom, 2019, Cancer.

Head and Neck CancersPractice Guidelines in Oncology

K. Ang, J. Shah, R. Weber, 2011 .

Mucosal melanoma of the head and neck.

J. Shah, R. Weber, G. Sanguineti, 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting

B. Fox, B. O'Sullivan, D. Brizel, 2017, Cancer.

Treatment De-Intensification for Patients With HPV-Positive Head and Neck Cancers

M. Gillison, 2022, The Journal of the National Comprehensive Cancer Network.

Karyoplasmic interaction selection strategy: a general strategy to detect protein-protein interactions in mammalian cells.

E. Fearon, G. Tomaselli, J. Casella, 1992, Proceedings of the National Academy of Sciences of the United States of America.

Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: results of Eastern Cooperative Oncology Group Study E2399.

A. Cmelak, Sigui Li, M. Goldwasser, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Discrimination between related DNA sites by a single amino acid residue of Myc-related basic-helix-loop-helix proteins.

C. Dang, M. Gillison, C. Dolde, 1992, Proceedings of the National Academy of Sciences of the United States of America.

The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers.

Barbara Messing, Carole Fakhry, Stephanie Coquia, 2014, Oral oncology.

Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.

J. J. Lee, A. Gillenwater, M. Medvedovic, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Comprehensive control of human papillomavirus infections and related diseases.

M. Poljak, D. Forman, J. Cuzick, 2013, Vaccine.

Human Papillomavirus and Head and Neck Cancer

A. Chaturvedi, M. Gillison, 2010 .

Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.

Melissa L. Johnson, R. Cohen, M. Gillison, 2021 .

Molecular Pathways Human Papillomavirus in Head and Neck Cancer : Its Role in Pathogenesis and Clinical Implications

C. Chung, M. Gillison, 2009 .

The Alpha, Beta, Gammas of Oral Human Papillomavirus Infection and Head and Neck Cancer Risk.

M. Gillison, D. Rollison, 2016, JAMA oncology.

A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL.

J. Machiels, M. Ahn, T. Seiwert, 2016 .

A Longitudinal Study of Human Papillomavirus 16 L1, E6, and E7 Seropositivity and Oral Human Papillomavirus 16 Infection

Ross D. Cranston, J. Margolick, E. Sugar, 2015, Sexually transmitted diseases.

Impact of prophylactic human papillomavirus (HPV) vaccination on oral HPV infections among young adults in the U.S.

B. Graubard, A. Chaturvedi, M. Gillison, 2017 .

Dynamic factors affecting HPV-attributable fraction for head and neck cancers.

M. Gillison, J. Shewale, 2019, Current opinion in virology.

Racial differences in the relationship between tobacco, alcohol, and the risk of head and neck cancer: pooled analysis of US studies in the INHANCE Consortium

H. Morgenstern, A. Olshan, D. Winn, 2018, Cancer Causes & Control.

Estimating and explaining the effect of education and income on head and neck cancer risk: INHANCE consortium pooled analysis of 31 case‐control studies from 27 countries

H. Morgenstern, A. Olshan, W. Ahrens, 2015, International journal of cancer.

HPV knowledge gaps and information seeking by oral cancer patients.

M. Katz, M. Gillison, C. Fakhry, 2016, Oral oncology.

Smokeless Tobacco Use and the Risk of Head and Neck Cancer: Pooled Analysis of US Studies in the INHANCE Consortium.

H. Morgenstern, A. Olshan, D. Winn, 2016, American journal of epidemiology.

A Randomized Multi-Institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.

O. Harismendy, E. Vokes, T. Seiwert, 2022, Clinical Cancer Research.

The Biological Basis for Enhanced Effects of Proton Radiation Therapy Relative to Photon Radiation Therapy for Head and Neck Squamous Cell Carcinoma

Li Ma, H. Paganetti, J. Myers, 2021, International journal of particle therapy.

Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311).

E. Mendez, G. Weinstein, C. Chung, 2020 .

Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma.

V. Takiar, A. Molinolo, N. Dunlap, 2018 .

Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma.

M. Gillison, K. Akagi, Jingfeng Li, 2020, Cancer letters.

Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck

R. Weber, P. Nagarajan, S. Tam, 2021, Head and Neck.

Risk stratification after recurrence of human papillomavirus (HPV)‐related and non‐HPV‐related oropharyngeal cancer: Secondary analysis of NRG Oncology RTOG 0129 and 0522

M. Birrer, Q. Le, H. Bahig, 2021, Head & neck.

Human papillomavirus DNA detection, p16INK4a, and oral cavity cancer in a U.S. population.

M. Goodman, T. Thompson, E. Unger, 2019, Oral oncology.

Human papillomavirus DNA detection, pl6 INK4a , and oral cavity cancer in a U.S. population

Elizabeth, Mona, M. Goodman, 2019 .

Low etiologic fraction for human papillomavirus in larynx squamous cell carcinoma.

C. Resteghini, M. Gillison, B. Swanson, 2016, Oral oncology.

Molecular Epidemiology of Human Papillomavirus Infection

M. Gillison, 2008 .

Risk Prediction Models for Head and Neck Cancer in the US Population From the INHANCE Consortium

H. Morgenstern, A. Olshan, D. Winn, 2019, American Journal of Epidemiology.

Incidence trends for human papillomavirus-related (HPV-R) and unrelated (HPV-U) head and neck squamous cell carcinomas (HNSCC) in the United States (US)

A. Chaturvedi, W. Anderson, E. Engels, 2007 .

Bariatric Surgery for Morbid Obesity

M. Gillison, 2007 .

Biologic predictors of serologic responses to HPV in oropharyngeal cancer: The HOTSPOT study.

Gypsyamber D'Souza, K. Anderson, D. Chowell, 2015, Oral oncology.

Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium

H. Morgenstern, A. Olshan, R. Hayes, 2016, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Noninvasive genomic profiling of somatic mutations in oral cavity cancers.

Y. Xi, M. Gillison, K. Akagi, 2023, Oral oncology.

Nivolumab (Nivo) vs investigator’s choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.

K. Harrington, E. Vokes, R. Ferris, 2017 .

Proton Therapy for Head and Neck Cancer: A 12-Year, Single-Institution Experience

A. Garden, M. Chambers, B. Esmaeli, 2021, International journal of particle therapy.

Safety evaluation of nivolumab (Nivo) concomitant with cetuximab-radiotherapy for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG 3504.

W. Curran, R. Ferris, Q. Le, 2018 .

No role for human papillomavirus in esophageal squamous cell carcinoma in China

C. Abnet, P. Taylor, S. Dawsey, 2010, International journal of cancer.

HPV and its effect on head and neck cancer prognosis.

M. Gillison, 2010, Clinical advances in hematology & oncology : H&O.

Anticipation of the Impact of Human Papillomavirus on Clinical Decision Making for the Head and Neck Cancer Patient.

M. Gillison, Carlo Restighini, 2015, Hematology/oncology clinics of North America.

18F-FDG PET/CT Prediction of Treatment Outcomes in Human Papillomavirus–Positive, Locally Advanced Oropharyngeal Cancer Patients Receiving Deintensified Therapy: Results from NRG-HN002

J. Waldron, K. Sultanem, S. Yom, 2022, The Journal of Nuclear Medicine.

Development and validation of an individualized risk prediction model for oropharynx cancer in the US population

B. Graubard, A. Chaturvedi, H. Katki, 2019, Cancer.

Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma.

C. Chung, H. Quon, A. Sikora, 2015 .

E 1308: A phase II trial of induction chemotherapy (IC) followed by cetuximab with low dose versus standard dose IMRT in patients with human papilloma virus (HPV)-associated resectable squamous cell carcinoma of the oropharynx (OPSCC).

C. Chung, A. Cmelak, R. Ferris, 2013 .

Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141

K. Harrington, M. Monga, E. Vokes, 2017 .

Drug concentration-dependent DNA lesions are induced by the lipid-soluble antifolate, piritrexim (BW301U).

M. Gillison, R. Richards, O. Brown, 1986, Molecular Pharmacology.

Upper age limits for US male human papillomavirus vaccination for oropharyngeal cancer prevention: a microsimulation-based modeling study

B. Graubard, A. Chaturvedi, H. Katki, 2023, Journal of the National Cancer Institute.

Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance

Mingyao Li, A. Jazaeri, J. Ajani, 2023, Nature Medicine.

A Phase I Trial of Erlotinib and Concurrent Chemoradiotherapy for Stage III and IV (M0) Squamous Cell Carcinoma of the Head and Neck

R. Wahl, J. Gilbert, M. Rudek, 2012, Clinical Cancer Research.

Prognostic significance of human papillomavirus (HPV) tumor status for patients with head and neck squamous cell carcinoma (HNSCC) in a prospective, multi-center phase II clinical trial

A. Cmelak, W. Westra, J. Ridge, 2007 .

Safety Evaluation of Nivolumab Concomitant With Platinum-Based Chemoradiation therapy for Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504

W. Curran, R. Ferris, Q. Le, 2018 .

p16 expression as a human papillomavirus (HPV)-independent prognostic biomarker in non-oropharyngeal squamous cell carcinoma (non-OPSCC).

K. Ang, P. Harari, C. Chung, 2013 .

Association of serum cytokines with oral HPV clearance.

Ross D. Cranston, J. Margolick, R. Burk, 2016, Cytokine.

975TiP Phase Ib trial of ABBV-368 + tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and neck squamous cell carcinoma

J. Berlin, M. Blaney, J. Grewal, 2020 .

Adapting Head and Neck Cancer Management in the Time of COVID-19

M. Gillison, S. Porceddu, A. Lee, 2020, International Journal of Radiation Oncology, Biology, Physics.

Checkpoint inhibitors assessment in oropharynx cancer (CIAO): Safety and interim results.

Jason M. Johnson, J. Lee, J. Myers, 2019, Journal of Clinical Oncology.

Patient-Reported Outcomes after Intensity-Modulated Proton Therapy for Oropharynx Cancer

A. Garden, C. Fuller, E. Sturgis, 2021, International journal of particle therapy.

J OURNAL OF C LINICAL O NCOLOGY Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

P. Rosenberg, S. Altekruse, M. Goodman, 2014 .

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

J. Shah, R. Weber, A. Jimeno, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

R. Weber, A. Jimeno, M. Witek, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Safety and disease control achieved with the addition of nivolumab (Nivo) to chemoradiotherapy (CRT) for intermediate (IR) and high-risk (HR) local-regionally advanced head and neck squamous cell carcinoma (HNSCC): RTOG Foundation 3504.

W. Curran, R. Ferris, Q. Le, 2019, Journal of Clinical Oncology.

Burden of potentially human papillomavirus‐associated cancers of the oropharynx and oral cavity in the US, 1998–2003

S. Coughlin, M. Reichman, A. Giuliano, 2008, Cancer.

The INHANCE consortium: toward a better understanding of the causes and mechanisms of head and neck cancer.

A. Olshan, R. Hayes, D. Winn, 2015, Oral diseases.

Neoadjuvant Pembrolizumab is Active in Surgically Resected Head and Neck Cancer

K. Wilson, V. Takiar, N. Dunlap, 2018 .

Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC).

V. Takiar, N. Dunlap, F. Worden, 2021, Journal of Clinical Oncology.

Human immunodeficiency virus and lung cancer: differences in presentation and clinical course.

Richard D Moore, J. Herman, S. Baylin, 2005 .

Intratumoral heterogeneity and clonal evolution induced by HPV integration 1

K. Coombes, Sara Goodwin, F. Sedlazeck, 2023 .

Prevalence of and Risk Factors for Oral Human Papillomavirus Infection among HIV-Positive and HIV-Negative People Who Inject Drugs

Gregory D. Kirk, M. Gillison, S. Mehta, 2015, PloS one.

Risk factors for head and neck cancer in more and less developed countries: Analysis from the INHANCE Consortium.

H. Morgenstern, A. Olshan, W. Ahrens, 2022, Oral diseases.

Practice of Epidemiology Risk Prediction Models for Head and Neck Cancer in the US Population From the INHANCE Consortium

H. Morgenstern, A. Olshan, D. Winn, 2020 .

Prevalence of oral HPV infection in the United States, 2009-2010.

B. Graubard, A. Chaturvedi, M. Gillison, 2012, JAMA.

Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners.

K. Anderson, S. Pai, R. Haddad, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mouthwash use and cancer of the head and neck: a pooled analysis from the International Head and Neck Cancer Epidemiology Consortium

H. Morgenstern, A. Olshan, R. Hayes, 2016, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

The use of ultrasound in the search for the primary site of unknown primary head and neck squamous cell cancers.

U. Hamper, B. Messing, R. Blanco, 2014, Oral oncology.

Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial

Christopher U. Jones, E. Sturgis, P. Harari, 2019, The Lancet.

Oropharyngeal cancer survivorship in Denmark, 1977-2012.

M. Gillison, D. Eisele, C. Fakhry, 2015, Oral oncology.

Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.

C. Chung, H. Quon, A. Sikora, 2015, JAMA oncology.

Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States

P. Rosenberg, S. Altekruse, M. Goodman, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention and Epidemiology

B. Graubard, A. Scuteri, A. Chaturvedi, 2022 .